European healthcare systems face paying more for drugs or losing access to new treatments as a result of Donald Trump’s push for the global medicines industry to cut prices in the US, industry experts have warned.
Global drugmakers are in talks with the Trump administration as he pressures them to voluntarily reduce their prices for American patients.
Experts say the US president’s plan risks significant consequences for European healthcare systems, as both the Trump administration and pharmaceutical companies are likely to seek price increases in Europe to allow for cheaper costs in the US.
您已閱讀11%（596字），剩余89%（4855字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。